These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3580286)

  • 1. Time course and intensity of anthralin inflammation on involved and uninvolved psoriatic skin.
    Paramsothy Y; Lawrence CM
    Br J Dermatol; 1987 Apr; 116(4):517-9. PubMed ID: 3580286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthralin inhibits elevated levels of thioredoxin reductase in psoriasis. A new mode of action for this drug.
    Schallreuter KU; Pittelkow MR
    Arch Dermatol; 1987 Nov; 123(11):1494-8. PubMed ID: 2445297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The release and percutaneous permeation of anthralin products, using clinically involved and uninvolved psoriatic skin.
    Wang JC; Patel BG; Ehmann CW; Lowe N
    J Am Acad Dermatol; 1987 Apr; 16(4):812-21. PubMed ID: 3571544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skin polyamine levels in psoriasis: the effect of dithranol therapy.
    Bohlen P; Grove J; Beya MF; Koch-Weser J; Henry MH; Grosshans E
    Eur J Clin Invest; 1978 Aug; 8(4):215-8. PubMed ID: 100325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo study of skin mechanical properties in psoriasis vulgaris.
    Dobrev H
    Acta Derm Venereol; 2000; 80(4):263-6. PubMed ID: 11028858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy.
    Yamamoto T; Nishioka K
    Skin Pharmacol Appl Skin Physiol; 2003; 16(1):50-8. PubMed ID: 12566829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site variation in anthralin inflammation on forearm skin.
    Lawrence CM; Howel D; Shuster S
    Br J Dermatol; 1986 May; 114(5):609-13. PubMed ID: 3718851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescence remission spectroscopy of psoriatic lesions and the effect of topical anthralin therapy.
    Wollina U; Schmidt WD; Koch A; Scheibe A; Erfurth F; Fassler D
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1409-13. PubMed ID: 19508501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The response of uninvolved skin of patients with psoriasis to single and repeated applications of dithranol cream: an immunohistochemical assessment.
    Swinkels OQ; Prins M; van Vlijmen-Willems IM; Gerritsen MJ; van der Valk PG; van de Kerkhof PC
    Skin Pharmacol Appl Skin Physiol; 2002; 15(6):385-92. PubMed ID: 12476012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clearing of psoriasis documented by laser Doppler perfusion imaging contrasts remaining elevation of dermal expression levels of CD31.
    Hendriks AG; van de Kerkhof PC; de Jonge CS; Lucas M; Steenbergen W; Seyger MM
    Skin Res Technol; 2015 Aug; 21(3):340-5. PubMed ID: 25534374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of indomethacin on anthralin inflammation.
    Ramsay B; Rice N; Lawrence C
    Br J Dermatol; 1992 Mar; 126(3):262-5. PubMed ID: 1554602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsoriatic and proinflammatory action of anthralin. Implications for the role of oxygen radicals.
    Müller K
    Biochem Pharmacol; 1997 May; 53(9):1215-21. PubMed ID: 9214681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of the response of psoriasis to short-term application of anthralin.
    Marsden JR; Coburn PR; Marks J; Shuster S
    Br J Dermatol; 1983 Aug; 109(2):209-18. PubMed ID: 6871098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of H1-receptor blockade on anthralin inflammation.
    Speight EL; Ramsay B; Lawrence CM
    Skin Pharmacol; 1992; 5(1):25-8. PubMed ID: 1349488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of arachidonic acid on anthralin inflammation.
    Lawrence CM; Shuster S
    Br J Clin Pharmacol; 1987 Aug; 24(2):125-31. PubMed ID: 3113468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of anthralin inflammation. I. Dissociation of response to clobetasol and indomethacin.
    Lawrence CM; Shuster S
    Br J Dermatol; 1985 Jul; 113(1):107-15. PubMed ID: 4015967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The irritancy of anthralin is inhibited by repeat applications of a subirritant concentration.
    Parslew R; Friedmann PS
    Br J Dermatol; 1999 Sep; 141(3):469-74. PubMed ID: 10583050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo quantification of microvessels in clinically uninvolved psoriatic skin and in normal skin.
    Hern S; Mortimer PS
    Br J Dermatol; 2007 Jun; 156(6):1224-9. PubMed ID: 17459047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arachidonic acid and prostaglandin levels in dithranol erythema: time course study.
    Barr RM; Misch KJ; Hensby CN; Mallet AI; Greaves MW
    Br J Clin Pharmacol; 1983 Dec; 16(6):715-7. PubMed ID: 6661358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of steroid and dithranol therapy on cyclic nucleotides in psoriatic epidermis.
    Saihan EM; Albano J; Burton JL
    Br J Dermatol; 1980 May; 102(5):565-9. PubMed ID: 6248098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.